Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 151 to 160 of 862

TitleReference numberPublishedLast updated
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)TA965
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosisTA959
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TA960
Ritlecitinib for treating severe alopecia areata in people 12 years and overTA958
Momelotinib for treating myelofibrosis-related splenomegaly or symptomsTA957
Dupilumab for treating moderate to severe prurigo nodularisTA955
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedemaTA953
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and overTA956
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA954
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952

Results per page

  1. 10
  2. 25
  3. 50
  4. All